Company: EDSA
Filing Date: 2025-03-11
Form Type: 424B3
Source: 0001171843-25-001403
Chunk: 8

Company: Edesa Biotech, Inc.
Filing Date: 2025-03-11
Form: 424B3
Chunk 8
---

a result of new information, future results, events, developments or otherwise, unless required to do so by a governmental authority or
applicable law. We advise you, however, to review any further disclosures we make on related subjects in our most recent Annual Report
on Form 10-K, as well as any amendments thereto reflected in subsequent filings with the SEC.

| 6 |

### USE OF PROCEEDS
All of our common shares offered by this prospectus are being
registered for the accounts of the Selling Shareholders, and we will not receive any proceeds from the sale of the common shares.

| 7 |

### SELLING SHAREHOLDERS
This prospectus covers the resale or
other disposition by the Selling Shareholders identified in the table below of up to an aggregate of 7,812,496 common shares, which are
comprised of (i) 3,468,746 Shares and (ii) 4,343,750 Conversion Shares.

The Selling Shareholders acquired their
securities in the transaction described above under the heading “Prospectus Summary – Recent Developments – Private
Placement.”

The table below sets forth, as of February 28, 2025, the following information regarding
the Selling Shareholders:

| · | the name of the Selling Shareholder; |

| · | the number of common shares owned by the Selling Shareholder prior to this offering, without regard to any beneficial ownership limitations; |

| · | the number of common shares to be offered by the Selling Shareholder in this offering; |

| · | the number of common shares to be owned by the Selling Shareholder assuming the sale of all of the common shares covered by this prospectus; 
 and                                                                                                                                          |

Except as described above, the number
of common shares beneficially owned by the Selling Shareholder has been determined in accordance with Rule 13d-3 under the Exchange Act
and includes, for such purpose, common shares that the Selling Shareholder has the right to acquire within 60 days of February 28, 2025.

All information with respect to the
common share ownership of the Selling Shareholders has been furnished by or on behalf of the Selling Shareholders. We believe, based on
information supplied by the Selling Shareholders, that except as may otherwise be indicated in the footnotes to the table below, the Selling
Shareholders have sole voting and dispositive power with respect to the common shares reported as beneficially owned by it. Because the
S